Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes
to melanoma progression and resistance to BRAF pathway inhibition. Here we show that …

The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical
outcome of BRAF V600E metastatic melanoma. However, resistance to such compounds …

Introduction PolycombGroup (PcG) proteins maintain gene repression through histone
modifications and have been implicated in stem cell regulation and cancer. EZH2 is part of …

PolycombGroup (PcG) proteins are epigenetic silencers involved in maintaining cellular
identity, and their deregulation can result in cancer [1]. Mice without the PcG gene Bmi1 are …

Prostate cancer (PCa) is a major lethal malignancy in men, but the molecular events and their
interplay underlying prostate carcinogenesis remain poorly understood. Epigenetic events …

Introduction Treatment of breast cancer is becoming more individualized with the recognition
of tumor subgroups that respond differently to available therapies. Breast cancer 1 gene (…

Background Mouse xenografts from (patient-derived) tumors (PDX) or tumor cell lines are
widely used as models to study various biological and preclinical aspects of cancer. However, …

Background & Aims The polycomb repressive complex 2 (PRC2) regulates differentiation by
contributing to repression of gene expression and thereby stabilizing the fate of stem cells …

The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show
promising results, but drug resistance often limits durable clinical responses. There is a need for …

Tuberous sclerosis complex (TSC) is a rare neurodevelopmental disorder resulting from
autosomal dominant mutations in the TSC1 or TSC2 genes, leading to a hyperactivated …